Cargando…

Durvalumab plus novel agents in non-small cell lung cancer—a new COAST on the horizon?

Detalles Bibliográficos
Autores principales:	Dempke, Wolfram C. M., Fenchel, Klaus, Reuther, Susanne, Murphy, Michael F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073750/ https://www.ncbi.nlm.nih.gov/pubmed/35529785 http://dx.doi.org/10.21037/tlcr-21-1002

Ejemplares similares

Oncogene alterations in non-small cell lung cancer—have we MET a new target?
por: Dempke, Wolfram C. M., et al.
Publicado: (2022)

Has programmed cell death ligand-1 MET an accomplice in non-small cell lung cancer?—a narrative review
por: Dempke, Wolfram C. M., et al.
Publicado: (2021)

Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2022)

Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
por: Cascone, Tina, et al.
Publicado: (2023)

Contamination Rate of Cryopreserved Umbilical Cord Blood Is Inversely Correlated with Volume of Sample Collected and Is also Dependent on Delivery Mode
por: Reuther, Susanne, et al.
Publicado: (2022)

PD-L1 expression on tumor cells as a potential predictive biomarker for patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
por: Käsmann, Lukas, et al.
Publicado: (2023)

Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis
por: Manz, Kirsi M., et al.
Publicado: (2019)

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
por: Shaverdian, Narek, et al.
Publicado: (2020)

Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma
por: Cheng, Li, et al.
Publicado: (2021)

Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition
por: de Silva, Madhawa, et al.
Publicado: (2020)

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
por: Capdevila, J., et al.
Publicado: (2023)

Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block
por: Hockenhull, Kimberley, et al.
Publicado: (2021)

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
por: Alt, Marie, et al.
Publicado: (2023)

Perspectives and horizons of non-intubated robotic-assisted tracheal surgery
por: Metelmann, Isabella B., et al.
Publicado: (2021)

First-line cytotoxic chemotherapy regimen for non-small cell lung cancer in the elderly population: plus ça change
por: Dy, Grace K., et al.
Publicado: (2020)

An Uncommon Case of Myocarditis Secondary to Durvalumab Plus Tremelimumab
por: Diaz-Rodriguez, Porfirio E, et al.
Publicado: (2023)

Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases
por: Shiraishi, Yoshimasa, et al.
Publicado: (2022)

First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
por: Li, Lijuan, et al.
Publicado: (2023)

Durvalumab for urothelial carcinoma, non-small cell lung cancer
Publicado: (2019)

First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
por: Hotta, Katsuyuki, et al.
Publicado: (2021)

Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
por: Villaflor, Victoria M., et al.
Publicado: (2013)

Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
por: Arru, Caterina, et al.
Publicado: (2021)

Broadening the Genetic Horizons of CADASIL: New Variants of the NOTCH3 Gene Revealed and their Association with CADASIL
por: Mishra, Biswamohan, et al.
Publicado: (2023)

Allelic variability in PSA & AR genes: A novel biomarker on the horizon for carcinoma prostate
por: Dogra, P.N.
Publicado: (2014)

Probiotics, prebiotics & synbiotics in small intestinal bacterial overgrowth: Opening up a new therapeutic horizon!
por: Chen, Wei Chung, et al.
Publicado: (2014)

nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
por: Morgensztern, Daniel, et al.
Publicado: (2021)

Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer
por: Yamaguchi, Teppei, et al.
Publicado: (2019)

Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC
por: Borghetti, Paolo, et al.
Publicado: (2022)

New Horizons
por: Dogra, Vikram
Publicado: (2011)

Expanding horizons
Publicado: (2009)

Beyond the horizons
por: Natarajan, Sundaram
Publicado: (2015)

Commentary: Expanding the horizons of red-free examination
por: Soni, Tanvi, et al.
Publicado: (2022)

Commentary: Behçet’s uveitis – Expanding treatment horizons
por: Moreker, Mayur R
Publicado: (2023)

The Biodevelopment of Sexual Orientation: Beyond the Known Horizon
por: Dragan, Wojciech Ł., et al.
Publicado: (2022)

Novel and Emerging Tools and Technologies in Cardiac Electrophysiology: What’s on the Horizon in 2020?
por: Aryana, Arash
Publicado: (2019)

Ureteral stents are part of an ever-expanding technology horizon
por: Chi, Thomas, et al.
Publicado: (2014)

Digital Mental Health Challenges and the Horizon Ahead for Solutions
por: Balcombe, Luke, et al.
Publicado: (2021)

New horizons in Biophysics
por: Moylan, Elizabeth C
Publicado: (2011)

New Horizons in Diabetology
por: Tootee, Ali, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6m0teit5fskipu8jnpn3tqt41q